

New ultra-long-acting basal insulin: Insulin degludec

*N.J. Paw, N. Suksomboon**

Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.

Abstract

Long-acting basal insulin analogs were introduced in clinical practice for more than 10 years ago and designed to provide basal insulin requirement for both Type 1 (T1DM) and Type 2 (T2DM) diabetes mellitus. However, there has been a concern with the existing basal insulin such as insulin glargine 100U (IGla 100U) and insulin detemir (IDet) because of the risk of hypoglycemia, weight gain, management complexity and rigid dosing schedule associated with their pharmacokinetic and pharmacodynamic properties. Recently, US Food and Drug Administration (FDA) approved new long-acting basal insulin analog, insulin degludec (IDeg) in 2015. IDeg was derived from human insulin by removal of B30 threonine amino acid residue and acylating the DesB30 at the LysB29 with hexadecandioic acid via a gamma-L-glutamic acid spacer. IDeg has long half-life, providing flat, peakless and stable blood glucose lowering effect when injected once daily. Clinical studies have shown that IDeg is not superior to IGla 100U in antihyperglycemic efficacy but it has significant lower hypoglycemic episode. Moreover, IDeg has less blood glucose variability and broad dosing window with flexible dosing interval. Coformulation of IDeg with Insulin Aspart (IAsp) and Glucagon-like-peptide receptor agonist (GLP-1 agonist) have been designed for basal-bolus administration. They have a benefit of improvement in glycated haemoglobin and reduce the number of daily doses. Overall, IDeg, with its unique pharmacokinetic properties, will provide effective glycemic control while minimizing the risk of hypoglycemia.

Keyword: Long-acting-basal insulin, Insulin Degludec, Type 1 diabetes mellitus, Type 2 diabetes mellitus, Coformulation, Hypoglycemia.

1. INTRODUCTION

Patients with diabetes often require insulin supplementation to maintain optimal blood glucose level in order to prevent the undesirable complications of diabetes. Over a past decade, long acting basal insulin analogs have a contribution to improvement in diabetes management. The main role of basal insulin is to limit hepatic glucose production and lipolysis in the fasting state, particularly overnight, without impairing glucose availability for brain function.¹ Basal insulin is essential for all patients with both T1DM and T2DM. Unlike endogenous insulin which is secreted from pancreas in glucose dependent manner, the dose of currently available basal insulin analogs should be titrated to maintain the

appropriate level to avoid hypoglycemia or hyperglycemia. Available basal insulin analogs had been IDet and IGla 100U. Unfortunately, IDet and IGla 100U have significant residual within-patient variability, short half-life, glycemic control less than 24 hours and less predictable glucose lowering effect with once-daily dosing. This can result in inadequate dose titration due to fear of hypoglycemia, restriction of patient's lifestyle and inflexible dosing regimen². Currently, US FDA has given marketing authorization to IDeg in September, 2015. It is an ultra-long-acting basal insulin which has been formulated with a depot, slow-release from the site of injection in order to address the unmet needs of basal insulins. It comparatively reduces within-subject variability and has fewer hypoglycemic

*Corresponding author: naeti.suk@mahidol.ac.th

episodes, more predictable glucose lowering effect and long duration of action (>42 hours) due to its unique, flat and stable pharmacokinetic properties. IDeg is also available in combination with insulin aspart (IAsp) and liraglutide³. IDeg is not routinely used in clinical practice. The purpose of this review is to discuss about the previous findings of IDeg with its pharmacokinetic and pharmacodynamic properties for application in clinical practice.

2. FORMULATION, STRUCTURE AND MECHANISM OF ACTION

IDeg is available in two strengths of 3 ml (U100) [1-80 units per injection, in steps of 1 unit] and 3 ml (U200) [2-160 units per injection, in steps of 2 units]. U200 is bioequivalent with U100 and gives the same amount of insulin but with the half of its volume, resulting in a single injection with low volume which is beneficial for patients requiring high daily insulin. IDeg is available in market as Tresiba 100U/ml, 3ml and 200U/ml, 3ml. Unlike other long acting insulin, IDeg can be given anytime of the day with wide dosing interval of 8-40 hours and once daily dosing regimen without compromising the safety and efficacy.^{4,5}

IDeg is modified from human insulin by removal of B30 threonine amino acid residue and acylating the DesB30 human insulin at the amino group of LysB29 with hexadecanoic acid via a gamma-L-glutamic acid spacer. IDeg (pH 7.4) is a clear, colorless solution with a pH-dependent solubility. It is formulated as a dihexamer in the presence of zinc and phenol at T₃R₃ state. After subcutaneous injection, with the removal of phenol, dihexamer self-dissociate into multihexamer and forms a depot formation at the site of injection at T₆ state. Subsequent diffusion of zinc from multihexamer results in a gradual disassembling to release monomers and then are absorbed in circulation and bind to insulin receptor.^{6,7}

3. PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES

IDeg has a terminal half-life of approximately 25 hours and a state of equilibrium

is reached in approximately 2-3 days of dose administration. The duration of action is above 42 hours and remained detectable in the circulation during the entire study period for up to 120 hours. It has high protein binding of > 99%. A pharmacokinetic study of IDeg dose (0.4, 0.6 and/or 0.8 U/kg subcutaneous, once daily injection for two 6-day treatment periods) in T2DM patients showed evenly distributed glucose lowering effect at all dose interval with the area under the curve (AUC) for each of 6 hours intervals being approximately 25% of total AUC (AUC_{GIR,τ,SS}). The glucose-lowering effect of IDeg for the first 12 hours after dosing was similar to that for the following 12 hours. AUC_{GIR,0-12h,SS}/AUC_{GIR,τ,SS} was close to 50% for all three dose levels.⁸ The pharmacokinetic and pharmacodynamic data for T1DM and T2DM are summarized in **Table 1**.^{8,9} IDeg has four times lower day-to-day pharmacodynamic variability than IGla 100U under steady state in T1DM patients. The supporting data was AUC_{GIR,0-24hrs,SS} coefficient variation (CV) 20% vs 82% (P < 0.0001) for IDeg and IGla 100U respectively.¹⁰ It also has two folds longer half-life than IGla 100U (mean terminal half-life 25.4 vs 12.5 hours) in a more evenly distributed and stable pharmacokinetic picture at the steady state in T1DM.¹¹

4. SPECIAL POPULATION

4.1. Children, Adolescents and Elderly patients

For IDeg, a two-period crossover trial was conducted in children (6-11 years), adolescents (12-17 years) and adults (18-65 years) with T1DM by administration of IDeg 0.4U/kg single dose and compared with IGla 0.4U/kg. No statistically significant difference in maximum concentration (C_{max}) of IDeg was observed. Estimated treatment ratio of C_{max,IDeg,SD} were 1.2, 95% confidence interval (CI) 0.9-1.60 for children/adults and 1.23, 95% CI 1.00-1.51 for adolescents/adults.¹² A multiple-dose two-period crossover study was conducted in younger adults (18-35 years) and elderly group (≥ 65 years) with T1DM by giving IDeg 0.4U/kg once daily for six days. Similar pharmacokinetic profile was observed in both populations with estimated

Table 1. Pharmacokinetic and Pharmacodynamic parameters of IDeg in T1DM and T2DM^{9,8}

Unit	T1DM study ⁹		T2DM study ⁸		
	100 U	200 U	100 U		
Dose	0.4 U/kg	0.4 U/kg	0.4U/kg	0.6 U/kg	0.8 U/kg
Number of subjects	33		22	37	21
Pharmacokinetic parameters					
AUC _{0-24h,SS,IDeg} (pmol_h/L)	112,358 (27)	110,805 (33)	89643.2 (35.0)	130164 (22.6)	177408 (26.5)
Geometric mean (CV)					
C _{max,SS,IDeg} (pmol/L)	6568 (26)	6065 (37)	-	-	-
Geometric mean (CV)					
AUC _{IDeg,0-12h,SS} / AUC _{IDeg,τ,SS}	55	53	53.3 (4.1)	52.5 (5)	52.7 (5.3)
Geometric mean (CV)					
t _{1/2,IDeg,SS} , h	-	-	24.6	24.4	26.8
Harmonic mean					
Pharmacodynamic parameters					
AUC _{GIR,τ,SS} , mg/kg	2,255	2,123	827.5	1694.0	2482.3 (45.5)
Geometric mean (CV)	(48)	(48)	(67.9)	(55.9)	

IDeg = Insulin Degludec, T1DM = Type 1 Diabetes Mellitus, T2DM = Type 2 Diabetes Mellitus, AUC_{0-24h,SS,IDeg} = Area under the steady-state serum IDeg concentration time curve during a dosing interval (τ = 0-24 hours), C_{max,SS,IDeg} = Maximum steady state IDeg concentration during a dosing interval τ, AUC_{IDeg,0-12h,SS}/AUC_{IDeg,τ,SS} = Area under the steady-state serum IDeg concentration time curve from 0 to 12 h divided by the same parameter from 0 to 24 h, CV= coefficient of variation (%), t_{1/2} = half life

mean age group ratios (elderly/younger adult) for $AUC_{IDeg, \chi, SS}$ and $C_{max, IDeg, SS}$ were 1.04, 95% CI 0.73-1.47 and 1.02, 95% CI 0.74-1.39 respectively.¹³ These data suggest that the ultra-long pharmacokinetic properties of IDeg was preserved in children and adults with T1DM. In summary, IDeg can be used in elderly patients (age ≥ 65 years), adolescents and children from the age of one year.¹⁴ However, dosage should be titrated according to individual basis to reduce the risk of hypoglycemia. Great caution should be taken in geriatric patients since greater sensitivity of some older patients to the effect of IDeg cannot be ruled out.

4.2. Renal and Hepatic impairment

Insulin clearance is specifically mediated by the trafficking and internalization of the insulin receptor. It might be more predominant in high albumin-bound insulin that cannot be filtered via renal route as easily as unbound 'free' insulin. So, renal and hepatic impairment may not have large effect on pharmacologic profiles of IDeg. A single dose (IDeg 0.4 U/kg),

open-label, parallel group trial was conducted in 30 subjects, dividing into five groups (6 person/group) according to their renal function: normal renal function [creatinine clearance (CrCl > 80 ml/min)], mild (CrCl 50-80 ml/min), moderate (CrCl 30-49 ml/min) or severe (CrCl < 30 ml/min) renal impairment or subjects with end stage renal disease (ESRD) requiring haemodialysis. There was no statistically significant difference between the groups. The data were shown in **Table 2**¹⁵. Another single dose (IDeg 0.4 U/kg), open-labelled parallel group study was conducted in 24 patients, allocated into 4 groups (n = 6 person/group) based on the level of hepatic function [normal hepatic function or stable hepatic impairment classified as mild, moderate, or severe (Child-Pugh grades A, B and C, respectively)]. No difference was observed in pharmacokinetic parameters in terms of AUC_{120hrs} , C_{max} and apparent clearance (CL/F). The data were presented in **Table 2**.¹⁶ In summary, no specific dosage adjustment is required in renal and hepatic impairment but glucose monitoring should be intensified and dosage should be adjusted on individual basis.

Table 2. Relationship between degree of renal or hepatic impairment and insulin degludec pharmacokinetic parameters^{15,16}.

Comparison of grades of renal/hepatic impairment	Renal impairment study ¹⁵		Hepatic impairment study ¹⁶		
	$AUC_{0-\infty}$	C_{max}	$AUC_{0-120hr}$	C_{max}	CL/F
Mild vs normal	1.11 (0.80-1.54)	1.14 (0.81-1.61)	0.95 (0.77-1.16)	0.90 (0.67-1.20)	1.05 (0.86-1.29)
Moderate vs normal	1.11 (0.80-1.53)	1.06 (0.76-1.49)	1.00 (0.82-1.22)	0.77 (0.58-1.03)	0.98 (0.80-1.19)
Severe vs normal	1.19 (0.86-1.65)	1.23 (0.87-1.73)	0.92 (0.74-1.14)	0.75 (0.55-1.02)	1.06 (0.85-1.31)
ESRD vs normal	1.02 (0.74-1.40)	1.05 (0.75-1.46)	N/A	N/A	NA

Data are expressed as ratio (90 % confidence interval). Pair-wise comparisons are shown for subjects with impaired renal function and those with normal renal function after a single dose of IDeg. Data in ESRD groups are based on pharmacokinetic profiles (excluding a haemodialysis session).¹⁴ For the data from the hepatic impairment study, the endpoints were log-transformed and analysed using an analysis of variance model with hepatic function group, sex and age at baseline as fixed effects.¹⁵ Abbreviation: $AUC_{0-\infty}$: area under the insulin degludec serum concentration-time curve from zero to infinity, $AUC_{0-120hr}$: area under the 120-hr serum insulin degludec concentration-time curve, C_{max} : maximum serum insulin degludec concentration, ESRD: end-stage renal disease, IDeg: insulin degludec, CL/F: apparent insulin degludec clearance, N/A: not available

5. EFFICACY

5.1. Insulin Degludec (IDeg)

The efficacy of IDeg was investigated in a large clinical trial programme (namely BEGIN studies) which involve >11,000 patients with T1DM and T2DM. IGla 100U was generally used as a comparator and overall randomization of patients ratio was between 2:1 and 3:1 in phase 3 studies. The efficacy was assessed by mean HbA1C reduction and mean change in fasting plasma glucose (FPG) at the end of trial. With the exception of IDeg compared with Sitagliptin, all the trials were non-inferiority trials and efficacy was confirmed if the upper bound of the two sided 95% CI for the estimated treatment difference (ETD) (IDeg minus comparator) was below or equal to the non-inferiority limit of 0.4%.¹⁷ The duration of studies is 26 to 52 weeks.

Studies of IDeg in T2DM showed that with titration of glycemic targets, IDeg has similar efficacy of HbA1C reduction with observed mean change in HbA1C range from approximately 0.93 to 1.52 % with IDeg and 1.09 to 1.35 % with comparators (sitagliptin, IGla, IDet).¹⁸⁻²⁷ There was a trend towards lower FPG level with IDeg compared with IGla in five trials namely BEGIN Once Long (2012), BEGIN basal bolus Type 2 (2012), BEGIN Low Volume (2013), Philis-TA et al. (2013) and Pan C et al. (2016). The data are shown in **Table 3**.

Likewise, clinical studies in T1DM showed that IDeg is non-inferior to IGla 100U in terms of mean HbA1C reduction concentration. IDeg was compared with IDet and IGla in BEGIN basal bolus type 1 study (2012), BEGIN Flex T1 (2013) and Davies M et al. (2016) with mealtime insulin as part of basal bolus regimen. The observed mean HbA1C reduction was ranged from 0.4 to 0.5 % for IDeg and 0.39 to 0.58 % for comparators. FPG decreased substantially in both IDeg and IGla in a basal bolus regimen. With IDeg, FPG reduction was evident at the first post baseline assessment (12 weeks) and the lower FPG was maintained until the end of the trial. The observed mean FPG reduction range from 22.9 to 46.8 mg/dl with IDeg and

from 11.3 to 25.1 mg/dl with comparator.²⁸⁻³⁰ The data are summarized in **Table 3**.

In summary, for both T1DM and T2DM, the mean HbA1C reduction of IDeg was not significantly different with comparators. The mean HbA1C reduction was ranged from 0.4 to 1.52 % for IDeg and 0.39 to 1.35 % for comparators. In insulin naïve patients, mean HbA1C reduction was ranged from 0.93 to 1.52 %¹⁸⁻²⁶ whereas in insulin treated patients, mean HbA1C reduction was ranged from 0.4 to 1.10 %.²⁷⁻³¹ The data are summarized in **Table 3**.

5.2. Insulin Degludec/Insulin Aspart (IDegAsp)

IDeg molecular structure can be coformulated with insulin aspart (IAsp) in the presence of Zinc and phenol without the risk of hybrid hexamer formation. IDegAsp is available in market as Ryzodec® 70/30, 100U/ml, 3ml which contain 70% of basal analog IDeg and 30% short-acting analog IAsp.³²

The studies which assess the efficacy of IDegAsp compared with Biphasic Aspart (BiAsp), IGla and IDet are 26 weeks, phase 3 studies which were conducted in insulin treated patients. For T2DM, the efficacy of IDegAsp was superior to IGla alone with mean HbA1C reduction of 1.4% vs 1.2% but inferior to BiAsp 30.³³⁻³⁵ For T1DM, the efficacy of IDegAsp was not significantly different with standard basal-bolus regimen (IDet + Asp) with mean HbA1C reduction of 0.75% vs 0.7%.⁴⁵ The efficacy data are expressed in **Table 4**.

5.3. Insulin degludec/Liraglutide (IDegLira)

IDegLira is a fixed-ratio combination of IDeg and GLP-1 receptor agonist (liraglutide). The efficacy of once daily, subcutaneous IDegLira as add-on therapy to oral antidiabetic drugs in adult patients (age ≥18 years) with T2DM was investigated in five 26-weeks, randomized multinational, treat-to-target, phase 3 trials (DUAL-I, II, III, IV and V), as well as a 26-week extension of the DUAL-I trial.

In T2DM insulin naïve patients, add on therapy of IDegLira provides better glycemic control than add-on insulin degludec, liraglutide or

Table 3. Efficacy of IDeg on the HbA1C and FPG reduction

Study	Population, Duration	Arm	Baseline HbA1C % \pm SD	Mean HbA1C reduction % \pm SD	ETD (%) for HbA1C reduction CI 95%	Baseline FPG mmol/L \pm SD	Mean FPG reduction mmol/L \pm SD	ETD mmol/L for FPG, CI 95%
BEGIN Once Long ¹⁸ 2012	T2DM Insulin naïve, 1year	IDeg100U N=773	8.2(0.8)	-1.06 (1.01)	0.09 (-0.04,0.22) P = NA	9.6(2.6)	-3.8 (3.04)	-0.43 (-0.74, -0.13) P= 0.005
		IGla 100U N=257	8.2(0.8)	-1.19 (0.97)		9.7(2.6)	-3.3(2.87)	
BEGIN Once Long Extension ¹⁹ 2013	T2DM Insulin naïve, 2 yrs	IDeg100U N=551	8.1(0.8)	-1.1	0.07 (-0.07,0.22) P=0.339	9.7(2.4)	-4.17	-0.36 (-0.67, -0.05) P=0.021
		IGla 100U N=174	8.2(0.8)	-1.3		9.5(2.4)	-3.56	
BEGIN Once Asia ²⁰ 2013	T2DM Insulin naïve, 26wk	IDeg100U N=289	8.4(0.8)	-1.24	0.11 (-0.03,0.24) P=NA	8.4(2.1)	-2.88	-0.09 (-0.41, 0.23) P=0.59
		IGla 100U N=146	8.5(0.8)	-1.35		8.6(1.9)	-2.97	
BEGIN Low Volume ²¹ 2013	T2DM Insulin Naïve, 26wks	IDeg200U N=228	8.3(1)	Both reduce	0.04 (-0.11,0.19) P=NA	9.2(2.9)	-3.7	-0.42 (-0.78, -0.06) P=NA
		IGla100U N=229	8.2(0.9)	-1.3 (1.01)		9.7(2.6)	-3.4	
BEGIN FLEX T2 ⁵ 2012	T2DM Insulin naïve or Insulin treated, 26wks	IDeg _{flex} 100U OD N=203	8.5(1)	-1.28	IDeg _{flex} OD vs IGla OD: 0.04 (-0.12,0.20) P=NA	9(2.6)	NA	IDeg _{flex} OD vs IDeg OD: -0.05 (-0.45, 0.35) P = NS IDeg _{flex} OD vs IGla OD: -0.42 (-0.82, -0.02) P=0.04
		IDeg 100U OD N=204	8.4(0.9)	-1.07		8.8(2.8)	NA	
		IGla 100U OD N=203	8.4(0.9)	-1.26		9(2.8)	NA	
BEGIN Once Simple ²² 2013	T2DM Insulin naïve, 26wks	IDeg _{Simple} N=111	8.1(0.9)	-1.09	-0.16 (-0.39,0.07) P=NA	9.3(2.6)	-3.27	-0.57 (-1.3,0.17) P=NA
		IDeg _{Stepwise} N=111	8.2(0.9)	-0.93		9.7(2.6)	-2.68	
Philis-TA et al. ²³ 2013	T2DM Insulin naïve, 26wks	IDeg100U N=225	8.8(1)	-1.52	-0.43 (-0.61, -0.24) P=NA	9.4(2.6)	-3.41	-2.17 (-2.59, -1.74) P=NA
		Sitagliptin N=222	9(1)	-1.09		9.9(3.1)	-1.24	

Table 3. Efficacy of IDeg on the HbA1C and FPG reduction

Study	Population, Duration	Arm	Baseline HbA1C % \pm SD	Mean HbA1C reduction % \pm SD	ETD (%) for HbA1C reduction CI 95%	Baseline FPG mmol/L \pm SD	Mean FPG reduction mmol/L \pm SD	ETD mmol/L for FPG, CI 95%	
Kadowaki et al. ²⁴ 2016	T2DM Japanese Insulin treated, 26wks	IDeg _{flex} 100U N=229	7.8(0.6)	-0.54 (0.76)	0.08 (-0.05, 0.22)	7.4(2)	-1.6	-0.18 (-0.48, 0.12)	
		IDeg _{fix} 100U N=229	7.8(0.6)	-0.62 (0.75)	P=NA	7.4(2)	-1.4	P=NA	
Pan C et al. ²⁵ 2016	T2DM Insulin naïve, 26wks	IDeg OD 100U N=555	8.3(0.9)	-1.3 (1.1)	-0.05 (-0.18, 0.08)	9.4(2.4)	-3.35 (2.91)	-0.26 (-0.53, 0.02)	
		IGla OD 100U N=278	8.3(0.8)	-1.2 (1)	P=NA	9.4(2.5)	-3.14 (2.71)	P=NA	
Zinman B et al. ²⁶ 2013	T2DM Insulin naïve, 26wks					IDeg _{3TWAM} Vs IGla			IDeg _{3TWAM} vs IGla
		BEGIN Easy (AM)	IDeg _{3TWAM} N=229	8.2(0.8)	-0.93	OD: 0.34 (0.18,0.51)	9.3(2.4)	NA	OD: 0.72 (0.29,1.14)
		BEGIN Easy (PM)	IGla OD N=230	8.3(0.9)	-1.28	P=NA	9.6(2.4)	NA	P=0.001
			IDeg _{3TWPM} N=233	8.3(0.8)	-1.09	IDeg _{3TWPM} vs IGla	9.9(2.2)	NA	IDeg _{3TWPM} vs IGla
BEGIN Compare ²⁷ 2014	T2DM Insulin treated 22wks	IDeg 200U N=186	8.1(0.9)	-0.8	-0.11 (-0.28, 0.05)	8.3(3)	-2.3	0.11 (-0.34, 0.55)	
		IDeg 100U N=187	8.2(0.9)	-0.7	P=NA	8.3(3.4)	-2.4	P=NA	
BEGIN BB T1 ²⁸ 2012	T1DM Insulin treated 52 wks	IDeg100U N=472	7.7(0.9)	-0.4 (SE0.03)	-0.01 (-0.14, 0.11)	9.1(4)	-1.3 (SE 0.2)	-0.33 (-1.03, 0.36)	
		IGla 100U N=157	7.7(1)	-0.39 (SE0.07)	P< 0.0001	9.7(4.4)	-1.4 (SE 0.4)	P=0.35	
Davies M et al. ²⁹ 2016	T1DM Insulin treated 1year	IDeg OD N=302	8(1)	-0.5	-0.01 (-0.17,0.14)	9.9(4)	-2.2	-1.11 (-1.83, -0.4)	
		IDet N=153	8(0.9)	-0.5	P=NA	9.5(4)	-0.8	P<0.05	

Table 3. Efficacy of IDeg on the HbA1C and FPG reduction

Study	Population, Duration	Arm	Baseline HbA1C % ± SD	Mean HbA1C reduction % ± SD	ETD (%) for HbA1C reduction CI 95%	Baseline FPG mmol/L ± SD	Mean FPG reduction mmol/L ±SD	ETD mmol/L for FPG, CI 95%
BEGIN FLEX T1 ³⁰ 2013	T1DM Insulin treated 26 wks	IDeg _{forced/flex} + IAsp N=164	7.7(1)	-0.4 (0.59)	IDeg _{forced/flex} vs IDeg: 0.01 (-0.13, 0.14) P=NA	9.6(4.1)	-1.28 (5.03)	IDeg _{forced/flex} vs IDeg: 0.95 (0.15,1.75) P=0.021
		IDeg+Asp N=165	7.7(0.9)	-0.41 (0.71)				
		IGla+Asp N=164	7.7(0.9)	-0.58 (0.72)				
BEGIN BBT2 ³¹ 2012	T2DM Insulin treated, 52wks	IDeg100U N=744	8.3(0.8)	-1.10	0.08 (-0.05,0.21) P=NA	9.2(3)	-2.3	-0.29 (-0.65, 0.06) P=0.1075
		IGla 100U N=248	8.4(0.9)	-1.18				

Note: ETD (mmol/L) for FPG in favor of IGla, mean ±SD; Abbreviations: CI: confidence interval; ETD: estimated treatment difference; FPG: fasting plasma glucose; IGla: Insulin Glargine, IDeg: Insulin degludec, IDegfix: Insulin degludec with fixed dose scheme; IDegflex: Insulin degludec with flexible dose scheme; IDegForced-Flex: Insulin degludec with forced-flexible scheme; IDet: detemir insulin; NA, not available; SD: standard deviation; NS: not significant; BBT1: Basal Bolus Type 1; BB T2: Basal Bolus Type 2, IDegSimple: IDeg simple algorithm with dose adjustment based on one pre-breakfast self-monitoring blood glucose measurement(SMBG), IDegStepwise: IDeg stepwise algorithm with dose adjustment based on three consecutive pre-breakfast SMBG values, IDeg 3TWAM=insulin degludec administered three times a week between waking up and first meal of day, IDeg 3TWPM=insulin degludec administered three times a week with the main evening meal, Sitagliptin: Sitagliptin 100mg OD, SD: Standard Deviation, SE: Standard Error

placebo or unchanged GLP-1 receptor agonists (ie liraglutide or exenatide). The HbA1C reduction range from 1.04 to 1.9 % in IDegLira and 0.16 to 1.4 % in comparators. For T2DM insulin experienced patients, IDegLira is superior to add-on insulin degludec or ongoing insulin glargine with HbA1C reduction range from 0.74 to 1.9 % in IDegLira and 0.39 to 1.13 % in comparators.³⁶⁻⁴³ The data are summarized in **Table 4**.

6. SAFETY

6.1. Hypoglycemia

6.1.1. Insulin Degludec (IDeg)

The results of BEGIN program related to hypoglycemia are expressed in **Table 5**. On

criterion of overall confirmed hypoglycemia rate in T2DM, BEGIN Once Long (2012), BEGIN Once Asia (2013) and BEGIN basal bolus type 2 (2012) showed similar (but not statistically significant) reduction of overall hypoglycemia (episode/patients/year) with IDeg compared with IGla 100U.

Pooled patient level data meta-analysis showed that in T2DM population, a significantly lower rate of overall confirmed and nocturnal confirmed hypoglycemic episodes were reported with IDeg compared with IGla 100U. The supporting data were rate ratio (RR) 0.83 (95% CI 0.74-0.94) for overall confirmed hypoglycemia and RR 0.68 (95% CI 0.57-0.82) for nocturnal confirmed hypoglycemia. For Type 1 DM, although there is no significant difference between IDeg

and IGla 100U in overall hypoglycemic episode [RR 1.10 (95% CI 0.96-1.26)], a lower rate of nocturnal hypoglycemia was seen in IDeg group compared with IGla 100U group [RR 0.83 (95% CI 0.69-1)] for entire treatment period.⁴⁴

In summary, for both T2DM and T1DM, a lower rate of nocturnal hypoglycemia was found in IDeg compared with IGla 100U.⁴⁴

6.1.2. Insulin Degludec/Insulin Aspart (IDegAsp)

When compared IDegAsp with IDet, both in combination with mealtime insulin aspart (IAsp), IDegAsp has a benefit of 37% reduction

in nocturnal hypoglycemia compared with IDet. The administration of IDegAsp with a single meal with additional bolus rapid-acting insulin at remaining meal time can simplify the treatment regimen in T1DM by reducing the number of daily injections (3 for IDegAsp and 4-5 for IDet) and a lower insulin dose.⁴⁵

Overall, for both T1DM and T2DM, the estimated rate of overall hypoglycemia and overall nocturnal hypoglycemia was lower in IDegAsp compared with comparators (IGla, BiAsp and IDet).^{33,34,35,45} The safety data of IDegAsp are summarized in **Table 6**.

Table 4. Efficacy of IDegAsp and IDegLira on HbA1C and FPG reduction

Study	Population Duration	Arm	Baseline HbA1C % ± SD	Mean HbA1C reduction % ± SD	ETD (%) for HbA1C reduction CI 95%	Baseline FPG mmol/L ± SD	Mean FPG reduction mmol/L ±SD	ETD mmol/L for FPG, CI 95%
Fulcher GR et al. ³³ 2014	T2DM Insulin treat- ed, ±OADs, 26wk	IDegAsp N=224	8.3(0.8)	-1.2	-0.03 (-0.18, 0.13) P=NA	8.9(2.9)	-3.1	-1.14 (-1.53, -0.76) P<0.001
		BiAsp 30 N=222	8.4(0.9)	-1.3		8.6(2.6)	-1.8	
Onishi Y et al. ³⁴ 2013	T2DM Japanese Insulin naïve, discontinue SU, DPP4i, glinides, 26wks	IDegAsp N=147	8.3(0.8)	-1.4 (0.9)	-0.28 (-0.46, -0.1) P < 0.01	9(1.6)	-3.3 (2.4)	0.15 (-0.29, 0.6) P=NS
		IGla N=149	8.5(0.8)	-1.2(1)		9.1(1.9)	-3.5 (2.4)	
Kaneko S et al. BOOST Asia ³⁵ 2015	T2DM Insulin treated, +MET, 26wks	IDegAsp N=280	8.4(0.8)	-1.38	0.05 (-0.1, 0.20) P=NA	7.9(2.5)	-2.5	-1.06 (-1.43, -0.7) P<0.001
		BiAsp 30 N=142	8.4(0.9)	-1.42		7.9(2.5)	-1.4	
Hirsch IB et al. ⁴⁵ 2012	T1DM Insulin treat- ed, 26wks	IDegAsp+	8.3(0.8)	-0.75	-0.05 (-0.18, 0.08) P=NA	10.3(4.7)	-1.6	0.23 (-0.46, 0.91) P=NS
		IAsp N=366	8.3(0.7)	-0.70		11.0(4.8)	-2.4	
		IDet+IAsp N=182						

Table 4. Efficacy of IDegAsp and IDegLira on HbA1C and FPG reduction

Study	Population Duration	Arm	Baseline HbA1C % ± SD	Mean HbA1C reduction % ± SD	ETD (%) for HbA1C reduction CI 95%	Baseline FPG mmol/L ± SD	Mean FPG reduction mmol/L ±SD	ETD mmol/L for FPG, CI 95%
BEGIN ADD TO GLP-1 ³⁶ 2016	T2DM Insulin naïve +MET± SU, DPP4i, exenatide, 26wks	IDeg +Lira N=174 Lira+Pbo N=172	7.6(0.6)	-1.04 (0.89)	-0.92 (-1.1, -0.75) P <0.0001	8.7(2.1)	NA	-2.55 (-3.07, -2.02) P <0.0001
BEGIN VICTOZA ADD-ON ³⁷ 2014	T2DM IDeg+MET treated 26wks	IDeg+Lira N=88 IDeg+Asp N=89	7.7(0.6)	-0.74	-0.32 (-0.53,- 0.12) P=0.0024	6.4(2.4)	-0.14	0.06 (-0.65, 0.77) P=NA
DUAL I ³⁸ 2014	T2DM, Insulin naïve + MET, PIO, 26wks	IDegLira N=833 IDeg N=413 Lira N=414	8.3(0.9)	-1.9 (1.1)	IDegLira vs IDeg: - 0.47 (-0.58,- 0.36) P<0.0001 IDegLira vs Lira: -0.64 (-0.75,0.53) P<0.0001	9.2(2.4)	-3.6	IDegLira vs IDeg: -0.17 (-0.41, 0.07) P=0.16 IDegLira vs Lira:- 1.76 (-2, -1.53) P < 0.0001
DUAL I extensio-n ³⁹ 2015	T2DM Insulin naïve + MET, PIO, 52wks	IDegLira N=833 IDeg N=413 Lira N=414	8.3(0.9)	-1.84	IDegLira vs IDeg: -0.46 (-0.57,- 0.34) P<0.0001 IDeLira vs Lira: -0.65 (-0.76,- 0.53) P < 0.0001	9.2(2.4)	-3.45	IDegLira vs IDeg: -0.20 (-0.45, 0.05) P=0.11 IDegLira vs Lira: -1.67 (-1.92, -0.42) P<0.0001
DUAL II ⁴⁰ 2014	T2DM Insulin treated +MET± SU, 26wks	IDegLira N=199 IDeg N=199	8.7(0.7)	-1.9	-1.1 (-1.3,-0.8) P < 0.0001	9.7(2.9)	-3.5 (2.9)	-0.73 (-1.19, -0.27) P= .0019

Table 4. Efficacy of IDegAsp and IDegLira on HbA1C and FPG reduction

Study	Population Duration	Arm	Baseline HbA1C % ± SD	Mean HbA1C reduction % ± SD	ETD (%) for HbA1C reduction CI 95%	Baseline FPG mmol/L ± SD	Mean FPG reduction mmol/L ±SD	ETD mmol/L for FPG, CI 95%
DUAL III ⁴¹ 2015	T2DM Insulin naïve Uncontrol GLP-1RA + MET ±PIO±SU, 26wks	IDegLira N=292	7.8	-1.3(0.8)	-0.94 (-1.11,- 0.78)	NA	-2.98 (2.28)	-2.64 (-3.03, -2.25)
		GLP-1RA N=146	7.4	-0.3(0.9)	P<0.001	NA	-0.6 (2.74)	P<0.001
DUAL IV ⁴² 2015	T2DM Insulin naïve, SU±MET 26wks	IDegLira N=435	7.9	-1.5	-1.02 P<0.001	9.1	-2.6	-2.3 P<0.001
		Pbo N=NA	7.9	-0.5		9.1	-0.3	
DUAL V ⁴³ 2016	T2DM Insulin treated +MET 26wks	IDegLira N=278	8.4(0.9)	-1.81 (1.08)	-0.59 (-0.74, -0.45)	160.5 (47.5)	-51	-0.15 (-6.28, 5.99)
		IGla N=279	8.2(0.9)	-1.13 (0.98)	P=NA	159.8 (52) mg/dl	-49.6 mg/dl	P=0.96

Abbreviation: T2DM: Type 2 diabetes mellitus, T1DM: Type 1 diabetes mellitus, IDeg: Insulin degludec 100U, IDegAsp: Insulin degludec/Insulin aspart 70/30, IDegLira: Insulin degludec 100U/ml + Liraglutide 3.6mg/ml, IGla: Insulin glargine 100U, IDet: Insulin Determir, Pbo: Placebo, BiAsp: Biphasic Aspart 70/30, GLP-1RA: Glucagon like peptide 1 receptor agonist, OADs: Oral antidiabetic drugs, MET:Metformin, SU:Sulphonylurea, PIO: Pioglitazone, DPP-4i: DPP-4 inhibitor, NA: Not available

Table 5. Safety of Insulin Degludec on overall hypoglycemia events and nocturnal hypoglycemia

Study	Population, Duration	Arm	Overall confirmed Hypoglycemia (PYE)	Estimated rate ratio of overall hypoglycemia (95% CI)	Overall nocturnal Hypoglycemia (PYE)	Estimated rate ratio of nocturnal hypoglycemia (95% CI)
BEGIN Once Long ¹⁸ 2012	T2DM Insulin naïve, 1year	IDeg 100U N=773	1.52	0.82 (0.64-1.04)	0.25	0.64 (0.42-0.98)
		IGla 100U N=257	1.85	P=0.106	0.39	P=0.038
BEGIN Once Long Extension ¹⁹ 2013	T2DM Insulin naive 2 years	IDeg 100U N=551	1.72	0.84 (0.68-1.04)	0.27	0.57 (0.40-0.81)
		IGla 100U N=174	2.05	P=0.115	0.46	P=0.002

Table 5. Safety of Insulin Degludec on overall hypoglycemia events and nocturnal hypoglycemia

Study	Population, Duration	Arm	Overall confirmed Hypoglycemia (PYE)	Estimated rate ratio of overall hypoglycemia (95% CI)	Overall nocturnal Hypoglycemia (PYE)	Estimated rate ratio of nocturnal hypoglycemia (95% CI)
BEGIN Once Asia ²⁰ 2013	T2DM Insulin naïve 26wks	IDeg 100U N=289 IGla 100U N=146	3.0 3.7	0.82 (0.60-1.11) P=0.20	0.8 1.2	0.62 (0.38-1.04) P=0.07
BEGIN FLEX T2 ⁵ 2012	T2DM Insulin naïve or treated 26wks	IDeg _{flex} OD N=203 IDeg OD N=204 IGla OD N=203	3.6 3.6 3.5	IDeg _{flex} /IDeg: 1.10 (0.79-1.52) P=NS IDeg _{flex} /IGla: 1.03 (0.75-1.40) P=NS	0.6 0.6 0.8	IDeg _{flex} /IDeg: 1.18 (0.66-2.12) P=NS IDeg _{flex} /IGla: 0.77 (0.44-1.35) P=NS
BEGIN Low Volume ²¹ 2013	T2DM Insulin naïve 26wks	IDeg 200U N=228 IGla 100U N=229	1.22 1.42	0.86 (0.58-1.28) P=0.46	0.18 0.28	0.64 (0.30-1.37) P=0.25
BEGIN Once Simple ²² 2013	T2DM Insulin naïve 26wks	IDeg _{Simple} N=111 IDeg _{Stepwise} N=111	1.60 1.17 P=0.4273	NA NA	0.21 0.1 P=0.2047	NA
Philis-TA et al. ²³ 2013	T2DM Insulin naïve 26wks	IDeg N=225 Sitagliptin N=222	3.07 1.26	3.81 (2.4-6.05) P<0.0001	0.52 0.3	1.93 (0.9-4.1) P=0.09
Kadowaki et al. ²⁴ 2016	T2DM Insulin treated, 26wks	IDe- g _{flex} 100U N=229 IDeg _{fix} 100U N=229	4.25 3.27	1.33 (0.95-1.86) P=NA	0.69 0.51	1.25 (0.71-2.20) P=NA
Pan C et al. ²⁵ 2016	T2DM Insulin naïve 26wks	IDeg OD 100U N=555 IGla OD 100U N=278	0.85 0.97	0.80 (0.59-1.10) P=NA	0.22 0.24	0.77 (0.43-1.37) P=NA

Table 5. Safety of Insulin Degludec on overall hypoglycemia events and nocturnal hypoglycemia

Study	Population, Duration	Arm	Overall confirmed Hypoglycemia (PYE)	Estimated rate ratio of overall hypoglycemia (95% CI)	Overall nocturnal Hypoglycemia (PYE)	Estimated rate ratio of nocturnal hypoglycemia (95% CI)
Zinman B et al. ²⁶ 2013	T2DM Insulin naïve 26wks	IDeg _{3TW} N=229	1.3	1.04 (0.69-1.55)	0.4	2.12 (1.08-4.16)
Easy (AM)		IGla OD N=230	1.2	P = 0.8583	0.2	P = 0.0291
Easy (PM)		IDeg _{3TW} N=233	1.6	1.58 (1.03-2.43)	0.2	0.60 (0.21-1.69)
		IGla OD N=234	1.0	P = 0.0365	0.2	P = 0.3357
BEGIN Compare ²⁷ 2014	T2DM Insulin treated 22wks	IDeg 200U N=186	5.17	0.96 (0.67-1.36)	1.27	0.93 (0.56-1.55)
		IDeg 100U N=187	5.66	P=NA	1.7	P=NA
BEGIN BB T1 ²⁸ 2012	T1DM Insulin treated, 52 wks	IDeg N=472	42.54	1.07 (0.89-1.28)	4.41	0.75 (0.59-0.96)
		IGla N=157	40.18	P=0.48	5.86	P=0.021
Davies M et al. ²⁹ 2016	T1DM Insulin treated, 1yr	IDeg OD N=302	37.78	0.95 (0.78-1.17)	3.38	0.67 (0.51-0.88)
		IDet N=153	39.26	P=NA	4.81	P < 0.05
BEGIN FLEX T1 ³⁰ 2013	T1DM Insulin Treated 26 wks	IDeg _{forced/flex} + IAsp N=164	82.4	IDeg _{forced/flex} vs IGla: 1.03 (0.85-1.26)	6.2	IDeg _{forced/flex} vs IGla: 0.6 (0.44-0.82)
		IDeg+Asp N=165	88.3	IDeg _{forced/flex} vs IDeg: 0.92 (0.76-1.12)	9.6	IDeg _{forced/flex} vs IDeg: 0.63 (0.46-0.86)
		IGla +Asp N=164	79.7		10	
BEGIN BB T2 ³¹ 2012	T2DM Insulin treated 52wks	IDeg 100U N=744	11.09	0.82 (0.69-0.99)	1.39	0.75 (0.58-0.99)
		IGla 100U N=248	13.63	P=0.0359	1.84	P=0.0399

Abbreviations: CI: confidence interval; IGla: Insulin Glargine 100U, IDeg: Insulin degludec 100U, IDegfix: Insulin degludec with fixed dose scheme; IDegflex: Insulin degludec with flexible dose scheme; IDegforced-flex, insulin degludec with forced-flexible scheme; IDet, Insulin detemir; NA, not available; NS: not significant; BBT1: Basal Bolus Type 1; BB T2: Basal Bolus Type 2, IDegSimple: IDeg simple algorithm with dose adjustment based on one pre-breakfast self-monitoring blood glucose measurement(SMBG), IDegStepwise: IDeg stepwise algorithm with dose adjustment based on three consecutive pre-breakfast SMBG values, Sitagliptin: Sitagliptin 100mg OD, PYE: Episode per patient per year

Table 6. Safety of IDegAsp and IDegLira in overall confirmed hypoglycemia and nocturnal hypoglycemia

Study	Population Duration	Arm	Overall Hypogly- cemia (PYE)	Estimated ratio of overall hypoglycemia (95% CI)	Overall nocturnal Hypoglycemia (PYE)	Estimated ratio of nocturnal hypoglycemia (95% CI)
Fulcher GR et al. ³³ 2014	T2DM Insulin treated ±OADs 26wks	IDegAsp N=224	9.72	0.68 (0.52-0.89)	0.74	0.27 (0.18-0.41)
		BiAsp 30 N=222	13.96	P=0.0049	2.53	P<0.0001
Onishi Y etal. ³⁴ 2013	T2DM Japanese Insulin naïve, Discontinue SU, DPP4i 26wk	IDegAsp N=147	1.91	0.73 (0.5-1.08)	0.39	0.75 (0.34-1.64)
		IGla N=149	2.71	P=NS	0.53	P=NS
Kaneko S et al. BOOST Asia ³⁵ 2015	T2DM Asian Insulin treated +MET 26wks	IDegAsp N=280	9.6	1.00 (0.76-1.32)	1.1	0.67 (0.43-1.06)
		BiAsp 30 N=142	9.5	P=NS	1.6	P=NS
Hirsch IB et al. ⁴⁵ 2012	T1DM Insulin treated 26wks	IDegAsp N=366	39.17	0.91 (0.76-1.09)	3.71	0.63 (0.49-0.81)
		IDet N=182	44.34	P=NS	5.72	P<0.05
BEGIN ADD TO GLP- ³⁶ 2016	T2DM Insulin naïve+ MET±SU, DPP4i,exenatide 26wks	IDeg+Lira N=174	0.57	4.67 (2.07-10.56)	0.05	1.75 (0.24-12.71)
		IDeg+Pbo N=172	0.12	P=0.0002	0.03	P=NS
BEGIN VICTOZA ADD-ON ³⁷ 2014	T2DM Insulin treated +MET ±DPP4i 26wks	IDeg+Lira N=88	1	0.13 (0.08-0.21)	0.17	0.14 (0.05-0.40)
		IDeg+Asp N=89	8.15	P<0.0001	1.11	P=0.0002
DUAL I ³⁸ 2014	T2DM Insulin naïve + MET, PIO 26wks	IDegLira N=825	1.8	IDegLira vs Lira: 7.61 (5.17-11.21)	0.2	NA
		IDeg N=412	2.6	P<0.0001	0.3	
		Lira N=412	0.2	IDegLira vs IDeg: 0.68 (0.53-0.87)	0.03	
				P=0.0023		

Table 6. Safety of IDegAsp and IDegLira in overall confirmed hypoglycemia and nocturnal hypoglycemia

Study	Population Duration	Arm	Overall Hypogly- cemia (PYE)	Estimated ratio of overall hypoglycemia (95% CI)	Overall nocturnal Hypoglycemia (PYE)	Estimated ratio of nocturnal hypoglycemia (95% CI)
DUAL I extension ³⁹ 2015	T2DM Insulin naïve + MET, PIO 52wks	IDegLira N=833	1.767	IDegLira vs IDeg: 0.63 (0.5-0.79) P<0.0001	0.223	IDegLira vs Lira: 11.99 (4.85-29.63) P<0.0001
		IDeg N=413	2.791		0.366	
		Lira N=414	0.191	IDegLira vs Lira: 8.52 (6.09-11.93) P<0.0001	0.018	IDegLira vs IDeg: 0.68 (0.44-1.06) P=0.09
DUAL II ⁴⁰ 2014	T2DM Insulin treated +MET, ±SU 26wks	IDegLira N=199	1.5	0.66 (0.39-1.13) P=NS	0.22	0.81 (0.35-1.90) P=NS
		IDeg N=199	2.6		0.32	
DUAL III ⁴¹ 2015	T2DM Insulin naïve Un- control GLP-1+ MET±PIO±SU 26wks	IDegLira N=292	2.82	25.4 (10.6-60.5) P<0.001	NA	NA
		GLP-1 RA N=146	0.12		NA	
DUAL IV ⁴² 2015	T2DM Insulin naïve +SU ± MET 26wks	IDegLira +OADs N=435	3.5	3.74 P < 0.001	NA	NA
		Pbo +OAD N=NA	1.4		NA	NA
DUAL V ⁴³ 2016	T2DM Insulin treated +MET 26wks	IDegLira N=278	2.23	0.43 (0.30-0.61) P < 0.001	0.22	0.17 (0.10-0.31) P < 0.001
		IGla _{2TW} N=279	5.05		1.23	

Abbreviation: T2DM: Type 2 diabetes mellitus, T1DM: Type 1 diabetes mellitus, IDeg: Insulin degludec 100U, IDegAsp: Insulin degludec/Insulin aspart 70/30, IDegLira: Insulin degludec 100U/ml + Liraglutide 3.6mg/ml, IGla: Insulin glargine 100U, IDet: Insulin Determir, Pbo: Placebo, BiAsp: Biphasic Aspart 70/30, GLP-1RA: Glucagon like peptide 1 receptor agonist, OADs: Oral antidiabetic drugs, MET:Metformin, SU:Sulphonylurea, PIO: Pioglitazone, DPP-4i: DPP-4 inhibitor, NA: Not available, PYE: Episode per patient per year

6.1.3. Insulin degludec and Liraglutide (IDegLira)

Five 26 weeks, phase 3 trials (DUAL-I, II, III, IV and V) were conducted in T2DM. Add on IDegLira was associated with lower incidence of overall hypoglycemia and nocturnal hypoglycemia than add on IDeg in both insulin naïve patients or insulin experienced patients who are ongoing IGla.³⁸⁻⁴³ The data are summarized in **Table 6**.

6.2. Cardiovascular Safety

According to US FDA 2008 Cardiovascular Risk Guidance recommendation, a pre-specified meta-analysis of major adverse cardiovascular events (MACE) in phase 3 trials was carried out. In 16 clinical trials involving 8918 participants, 80 patients experienced treatment emergent MACE [53 patients in IDeg or Insulin degludec/Insulin Aspart (IDegAsp) group and 27 patients in comparator groups]. The incidence was observed in IDeg or IDegAsp group more than in comparator group [the incidence rate: 1.48 events per 100 patient-year of exposure (PYE) in patients treated with IDeg or IDegAsp vs 1.44 events per 100 PYE in patients treated with comparator basal insulins]. The DEVOTE (NCT 01959529) trial which is aiming to enroll 75,00 T2DM patients at high cardiovascular risk (age \geq 50 years with a history of cardiovascular disease or diabetic nephropathy or age \geq 60 years with cardiovascular risk factors) is expected to be available in 2018.⁴⁶

7. Starting dose, dose adjustment and switching therapy

7.1. Insulin Degludec (IDeg)⁴⁷⁻⁴⁸

For T2DM insulin naïve patients, the recommended starting dose for IDeg is 10U once daily. In T1DM insulin naïve patients, 0.2-0.4 U/kg of body weight can be calculated as initial total daily insulin dose and approximately 1/3 to 1/2 of total daily insulin dose should be administered as basal insulin for IDeg. The remainder is administered as short acting insulin and divided between each daily meal. The recommended day between dose increases is

3-4 days. The treat-to-target goal and insulin dose adjustment are based around an individual's pre-breakfast FPG (or self-monitoring plasma glucose) level. A calculated mean FPG from 2 preceding days can be compared to desired glycemic goals and insulin dose can be adjusted up or down by 2 units.

Switching to IDeg from other once daily basal insulin dose can usually be done on a 1:1 basis. Dose should be reduced by 20% if transitioning from a twice daily basal schedule and also depending upon individual glycemic response. When switching from a once-daily basal insulin, dose reduction can also be considered if the patients have low HbA1C. FPG should be closely monitored before, during and in the weeks following a switch to IDeg. When switching patients from other basal insulin to IDeg, it is necessary to manage a brief period between the loss of previous basal insulin's effect and attainment of steady state with IDeg. During this period, patients may observe higher blood glucose values of 3-5 days following the switch to IDeg and this should be discussed with patient prior to the switch. Dose and timing adjustment of concurrent short or rapid-acting insulin analogues or other glucose-lowering treatment may be required.

7.2. Insulin Degludec/Insulin Aspart (IDegAsp)⁴⁹

IDegAsp can be administered once or twice daily with any main meal. The starting dose for T2DM, insulin naïve patients is 10U once daily. For insulin naïve T1DM patients, the starting dose of Ryzodeg[®] is approximately 1/3 to 1/2 of total daily insulin dose. The remainder of total daily insulin dose can be administered as a short- or rapid- acting insulin divided between each daily meal. In general, 0.2 to 0.4 units of insulin unit/kg of body weight can be used to calculate as initial total daily insulin dose.

For switching therapy, for both T1DM and T2DM, if the patient is transferred from only once or twice daily basal insulin, start Ryzodeg[®] 70/30 at the same unit dose and injection schedule. For patients switching from once-daily basal insulin to once daily, Ryzodeg[®] 70/30, monitor blood glucose after starting therapy due to the

rapid-acting insulin component. If switch from multiple daily regimen which include both basal and short- or rapid- acting insulin at meal time, start Ryzodeg® 70/30 once daily with main meal at same unit dose as basal insulin and continue short- or rapid- acting insulin at same dose for meals not covered by Ryzodeg® 70/30. If the patient use once or twice daily premix or self-mix insulin, start with the same unit dose and injection schedule and if the patients also using short or rapid-acting insulin at mealtimes, continue the short- or rapid- acting insulin at the same dose for meals not covered by Ryzodeg® 70/30.

7.3. Insulin degludec/Liraglutide (IDegLira)⁵⁰⁻⁵¹

IDegLira is available in market as Xultophy® which contains IDeg 100 U/ml and liraglutide 3.6 mg/ml. One dose step contains 1U of IDeg and 0.036 mg of liraglutide. The maximum daily dose step is 50 dose steps (IDeg 50 U/liraglutide 1.8mg). For switching therapy, if the patient is not transferred from GLP-1 receptor agonist or basal insulin, the recommended starting dose is 10 U/0.36 mg once daily. If the patient is switched from GLP-1 receptor agonist or basal insulin, starting dose is 16 U/0.6 mg once daily and this starting dose should not be exceeded. When the patient is transferred from once weekly administered long-acting GLP-1 receptor agonist, initiate IDegLira at the same time as the next scheduled dose of long-acting GLP-1 receptor agonist. IDegLira can be added to existing oral anti-diabetic drugs (OADs) therapy; however, dose reduction for concomitantly administered sulphonylurea should be considered. IDegLira is not recommended in moderate or severe renal impairment, ESRD (end stage renal disease) and clinical experience in patients with hepatic impairment is currently too limited to recommend its use in these patients. Although pharmacokinetics of IDeg is not significantly affected by renal or hepatic impairment, liraglutide exposure was reduced in renal or hepatic impairment compared with healthy individuals.

Conclusion

All things considered, for both T1DM

and T2DM, IDeg lead to tight glycemic control with reduction of mean HbA1C % and reduce rate of hypoglycemic events, particularly nocturnal hypoglycemia. In special population including renal and hepatic impairment, there is no specific dosage adjustment for these populations. However, glucose monitoring should be intensified and dosage should be titrated according to individual requirement in these populations. IDeg, with its unique pharmacodynamic properties, by offering basal insulin with flexible dosing schedule, it can increase the patient's adherence and improve glycemic outcome.

REFERENCES

1. Sohilgenfeld R, Seipke G, Berchtold H, Owens DR. The evolution of insulin glargine and its continuing contribution to diabetes care. *Drugs*. 2014;74(8): 911-27
2. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. *Clin pharmacokinet*. 2014;53(9):787-800.
3. Thuillier P, Alavi Z, Kerlan V. Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes. *Diabetes Metab Syndr Obes*. 2015;1;8:483-93.
4. Korsatko S, Deller S, Koehler G, Mader JK, Neubauer K, Adrian CL, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. *Clin Drug Investig*. 2013; 33(7):515-21.
5. Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily. *Diabetes Care*. 2013;36(4):858-64.
6. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribell U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. *Pharm Res*. 2012;29(8):2104-14
7. Kalra S, Gupta Y. Clinical use of Insulin Degludec: Practical Experience and Pragmatic

- Suggestions. *N Am J Med Sci.* 2015;7(3): 81-5.
8. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. *Diabetes Obes Metab.* 2012;14(10):944-50.
 9. Korsatko S, Deller S, Koehler G, Mader JK, Neubauer K, Adrian CL et al. A comparison of the steady-state pharmacokinetic and pharmacodynamics profiles of 100 and 200U/ml formulations of ultra-long-acting insulin degludec. *Clin Drug Investig.* 2013; 33:515-521.
 10. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. *Diabetes Obes Metab.* 2012;14(9):859-64.
 11. Heise T, Hovelmann U, Nosek L, Bottcher S.G, Granhall C, Haahr H, et al. Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine.[abstract no.1046]. MINUTES of the 46th GENERAL ASSEMBLY of the EUROPEAN ASSOCIATION for the STUDY of DIABETES. 2010 Sep 23. *Diabetologia.* 2011;54:[Suppl1]S1-S542.
 12. Biester T, Blaesig S, Remus K, Aschemeier B, Kordonouri O, Granhall C, et al. Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. *Pediatr Diabetes.* 2014;15(1):27-33.
 13. Korsatko S, Deller S, Mader JK, Glettler K, Koehler G, Treiber G, et al. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus. *Drugs Aging.* 2014;31(1):47-53.
 14. European Medicines Agency. Tresiba (insulin degludec): EU summary of product characteristics [document on the Internet]. 2013 Jan 2 [cited 2016 Jul 23]. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf
 15. Kiss I, Arold G, Roepstorff C, Bottcher SG, Klim S, Haahr H. Insulin degludec: pharmacokinetics in patients with renal impairment. *Clin Pharmacokinet.* 2014 ;53(2):175-83
 16. Kupcova V, Arold G, Roepstorff C, Hojbjerre M, Klim S, Haahr H. Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. *Clin Drug Investig.* 2014 ;34(2):127-33.
 17. Mithal A, Kumar A, Jain SM, Kumar H. Efficacy without barriers to insulin therapy: lessons from the BEGIN trial programme. *J Assoc Physicians India.* 2014;62(1 Suppl): 27-34.
 18. Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). *Diabetes Care.* 2012; 35(12):2464-71.
 19. Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skjoth TV, et al. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. *Diabet Med.* 2013;30(11):1298-304.
 20. Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. *J Diabetes Investig.* 2013; 4(6):605-12.
 21. Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. *Diabetes Care.* 2013;36(9):2536-42.
 22. Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J. Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use). *Adv Ther.* 2013;30(6):607-22.

23. Philis-Tsimikas A, Del Prato S, Satman I, Bhargava A, Dharmalingam M, Skjoth TV, et al. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. *Diabetes Obes Metab.* 2013;15(8):760-6.
24. Kadowaki T, Jinnouchi H, Kaku K, Herslov ML, Hyllested-Winge J, Nakamura S. Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial. *J Diabetes Investig.* 2016;7(5):711-7.
25. Pan C, Gross JL, Yang W, Lv X, Sun L, Hansen CT, et al. A multinational, randomized, open-label, treat-to-target trial comparing insulin degludec and insulin glargine in insulin-naïve patients with type 2 diabetes mellitus. *Drugs RD.* 2016;16(2):239-49.
26. Zinman B, DeVries JH, Bode B, Russell-Jones D, Leiter LA, Moses A, et al. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naïve patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. *Lancet Diabetes Endocrinol.* 2013 ; 1(2):123-31.
27. Bode BW, Chaykin LB, Sussman AM, Warren ML, Niemeyer M, Rabol R, et al. Efficacy and safety of insulin degludec 200 U/mL and insulin degludec 100 U/mL in patients with type 2 diabetes (Begin: Compare). *Endocr Pract.* 2014;20(8):785-91.
28. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet.* 2012;379(9825): 1489-97.
29. Davies M, Sasaki T, Gross JL, Bantwal G, Ono Y, Nishida T, et al. Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial. *Diabetes Obes Metab.* 2016;18(1):96-9.
30. Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. *J Clin Endocrinol Metab.* 2013;98(3):1154-62.
31. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Munoz-Torres M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet.* 2012; ; 379(9825):1498-507.
32. Dardano A, Bianchi C, Del Prato S, Miccoli R. Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes. *Vasc Health Risk Manag.* 2014;10:465-75.
33. Fulcher GR, Christiansen JS, Bantwal G, Polaszewska-Muszynska M, Mersebach H, Andersen TH, et al. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. *Diabetes Care.* 2014;37(8):2084-90.
34. Onishi Y, Ono Y, Rabol R, Endahl L, Nakamura S. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. *Diabetes Obes Metab.* 2013;15(9):826-32.
35. Kaneko S, Chow F, Choi DS, Taneda S, Hirao K, Park Y, et al. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial. *Diabetes Res Clin Pract.* 2015;107(1):139-47.
36. Aroda VR, Bailey TS, Cariou B, Kumar S, Leiter LA, Raskin P, et al. Effect of adding insulin degludec to treatment in patients

- with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study). *Diabetes Obes Metab.* 2016;18(7):663-70.
37. Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). *Diabetes Obes Metab.* 2014; 16(7):636-44.
 38. Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. *Lancet Diabetes Endocrinol.* 2014;2(11):885-93.
 39. Gough SC, Bode BW, Woo VC, Rodbard HW, Linjawi S, Zacho M, et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. *Diabetes Obes Metab.* 2015;17(10):965-73.
 40. Buse JB, Vilsboll T, Thurman J, Blevins TC, Langbakke IH, Bottcher SG, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). *Diabetes Care.* 2014; 37(11):2926-33.
 41. Linjawi S, Bode B, Chaykin LB, Courreges J.-P, Handelsman Y, Lehmann L.M et al. Efficacy and safety of IDegLira (combination of insulin degludec + liraglutide), in insulin-naive patients with T2D uncontrolled on GLP-1 receptor agonist (GLP-1RA) therapy. Poster session presented at: American Diabetes Association 75th Scientific Sessions; 2015 Sep 16; Boston, MA.
 42. Rodbard HW, Bode B, Harris SB, Rose L, Lehmann L.M, Jarlov H et al. IDegLira in insulin-naïve patients with type 2 diabetes (T2D) inadequately controlled on sulfonylureas (SU) alone or in combination with metformin: the DUAL IV. Poster session presented at: American Diabetes Association 75th Scientific Sessions; 2015 Sep 16; Boston MA.
 43. Lingvay I, Manghi FP, Garcia-Hernandez P, Norwood P, Lehmann L, Tarp-Johansen MJ, et al. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients with Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. *JAMA.* 2016 Mar 1;315(9):898-907.
 44. Ratner RE, Gough SC, Mathieu C, Del Prato S, Bode B, Mersebach H, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. *Diabetes Obes Metab.* 2013 ;15(2):175-84.
 45. Hirsch IB, Bode B, Courreges JP, Dykiel P, Franek E, Hermansen K, et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. *Diabetes Care.* 2012; 35(11):2174-81.
 46. Food and Drug Administration. Insulin degludec and insulin degludec/insulin aspart treatment to improve glycemic control in patients with diabetes mellitus. [document on the internet]. 2012 [cited 2016 Jul 8]. Available from: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327017.pdf>
 47. Vora J, Cariou B, Evans M, Gross JL, Harris S, Landstedt-Hallin L, et al. Clinical use of insulin degludec. *Diabetes Res Clin Pract.* 2015 Jul;109(1):19-31.
 48. How to start and convert your patients to once-daily, long acting Tresiba [document on the internet]. Novo Nordisk: Tresiba Insulin degludec injection 200 units/ml [updated 2016 Mar, cited 2016 Jul 8].

- Available from: <https://www.tresibapro.com/prescribing-and-dosing/how-to-prescribe.html>
49. European Medicines Agency. Ryzodeg (insulin degludec/insulin aspart): EU summary of product characteristics [document on the Internet]. 2013 Jan 21 [cited 2016 Jul 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002499/WC500139011.pdf
50. Greig SL, Scott LJ. Insulin degludec/liraglutide: A review in type 2 diabetes. *Drugs*. 2015;75(13):1523-34.
51. European Medicines Agency. Xultophy 100 units/ml+3.6mg/ml solution for injection: EU summary of product characteristics [document on the internet]. 2014 [cited 2016 Jul 23]. Available from: http://ec.europa.eu/health/documents/community-register/2014/20140918129550/anx_129550_en.pdf